GLP-1 receptor agonists protect kidneys through anti-inflammatory, antioxidant, and anti-fibrotic pathways, confirmed by the landmark FLOW trial with semaglutide.
FLOW trial confirms benefitThe FLOW trial provided definitive clinical evidence that semaglutide slows kidney disease progression in type 2 diabetes
What the researchers found
GLP-1 receptor agonists protect kidneys through anti-inflammatory, antioxidant, and anti-fibrotic mechanisms, with clinical data from the FLOW trial confirming semaglutide slows kidney disease progression.
Why it matters
Chronic kidney disease affects hundreds of millions of people worldwide and has limited treatment options. Showing that GLP-1 drugs protect kidneys adds a major benefit beyond their effects on blood sugar and weight.
The numbers in context
The FLOW study tested semaglutide 1 mg vs. placebo. Recruitment ran from 2019 to May 2021. GLP-1 drugs were first introduced for diabetes in 2005 and obesity in 2014.
How the study worked
Pharmacophysiological review combining molecular mechanisms with clinical trial evidence.
Who was studied
Review covering molecular studies and clinical trials in patients with chronic kidney disease
What this study cannot tell us
This is a review article synthesizing existing data. The kidney-protective mechanisms described are based partly on animal and cell studies.
How to read the evidence
Rated strong: comprehensive review combining molecular mechanisms with clinical trial evidence, including the landmark FLOW trial.
When this study was published
Published in 2024. Includes FLOW trial results, making this one of the most current kidney protection reviews.
The bigger picture
Chronic kidney disease affects hundreds of millions worldwide with limited treatment options. GLP-1 drugs join SGLT2 inhibitors and finerenone as kidney-protective agents, giving nephrologists more tools.
Questions still open
- Can GLP-1 drugs and SGLT2 inhibitors be combined for additive kidney protection?
- Do all GLP-1 drugs provide equal kidney benefit?
Common questions
Do GLP-1 drugs protect the kidneys?
Should diabetic kidney disease patients take semaglutide?
Read the original research
Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective.
Jornal brasileiro de nefrologia, 46(4), e20240101
Citation
Rico-Fontalvo, Jorge; Reina, Maricely; Soler, María José; Unigarro-Palacios, Mario; Castañeda-González, Juan Pablo; Quintero, Javier Jiménez; Raad-Sarabia, María; Moraes, Thyago Proença de; Daza-Arnedo, Rodrigo. (2024). Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective.. Jornal brasileiro de nefrologia, 46(4), e20240101. https://doi.org/10.1590/2175-8239-JBN-2024-0101en